Head-To-Head Review: Xylo Technologies (NASDAQ:XYLO) and Clarivate (NYSE:CLVT)

Xylo Technologies (NASDAQ:XYLO) and Clarivate (NYSE:CLVT) are both business services companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Xylo Technologies and Clarivate, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xylo Technologies	0	0	0	0	0.00
Clarivate	1	2	0	0	1.67

Clarivate has a consensus price target of $5.00, suggesting a potential upside of 15.87%. Given Clarivate’s stronger consensus rating and higher probable upside, analysts plainly believe Clarivate is more favorable than Xylo Technologies.

Valuation and Earnings

This table compares Xylo Technologies and Clarivate”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xylo Technologies	$29.86 million	0.13	-$16.02 million	N/A	N/A
Clarivate	$2.53 billion	1.17	-$911.20 million	($0.97)	-4.45

Xylo Technologies has higher earnings, but lower revenue than Clarivate.

Profitability

This table compares Xylo Technologies and Clarivate’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xylo Technologies	N/A	N/A	N/A
Clarivate	-24.90%	9.10%	3.93%

Insider and Institutional Ownership

0.3% of Xylo Technologies shares are held by institutional investors. Comparatively, 85.7% of Clarivate shares are held by institutional investors. 2.2% of Xylo Technologies shares are held by company insiders. Comparatively, 23.2% of Clarivate shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Xylo Technologies has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Clarivate has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.

Summary

Clarivate beats Xylo Technologies on 9 of the 11 factors compared between the two stocks.

About Xylo Technologies

Xylo Technologies Ltd, a technology-based company, provides medical-related devices and products in the United States, Europe, Asia, Israel, and internationally. The company operates through Corporate, E-commerce, Online Advertising & Internet Traffic Routing, Online Event Management, and Others segments. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it provides digital advertising platform; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops wireless vehicle battery charging technologies and modular electronic vehicles. The company was formerly known as Medigus Ltd. and changed its name to Xylo Technologies Ltd in April 2024. Xylo Technologies Ltd was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.

About Clarivate

Clarivate Plc operates as an information services provider in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. It operates through three segments: Academia & Government, Life Sciences & Healthcare, and Intellectual Property. The company offers Web of Science and InCites, that analyzes and explores the academic research landscape and manages research information; ProQuest One and Ebook Central that provides comprehensive content collections to institutions in a cost-effective manner; and Alma and Polaris, that manages academic resources and services, connect users, and support research publications. It also provides Patent and Trademark Renewals, that supports paralegal and admin tasks throughout the patent and trademark protection and maintenance process; CompuMark and Derwent, that supports critical decisions around patent and trademark protection, risk, and value creation throughout the innovation and brand lifecycle; IPFolio and Foundation IP that creates a structured environment for the protection and management of global patent and trademark assets. In addition, the company offers Cortellis Competitive Intelligence and Cortellis Drug Discovery Intelligence, that supports the development of new drugs and medical devices from discovery to clinical trials; Cortellis Regulatory Intelligence and OFF-X to monitor drug safety issues and adhere to regulatory protocols; Real World Data and Optimize that inform commercial launch strategy and set pricing for optimal reimbursement. It serves corporations, universities, law firms, government agencies, public libraries, and other professional services organizations. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc was founded in 1864 and is headquartered in London, the United Kingdom.